Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.

@article{Tan2018EngineeringVT,
  title={Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.},
  author={Yee Sun Tan and Kanokwan Sansanaphongpricha and Mark Prince and Dawei Sun and G T Wolf and Yan Lin Lei},
  journal={Journal of dental research},
  year={2018},
  volume={97 6},
  pages={
          627-634
        }
}
The recent Food and Drug Administration's approval of monoclonal antibodies targeting immune checkpoint receptors (ICRs) for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) offers exciting promise to improve patient outcome and reduce morbidities. A favorable response to ICR blockade relies on an extensive collection of preexisting tumor-specific T cells in the tumor microenvironment (TME). ICR blockade reinvigorates exhausted CD8+ T cells and enhances immune killing… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 64 REFERENCES

Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2015
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL